EichorEICHOR
Location: Chino Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Chino

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Phase 3 · Inland Psychiatric Medical Group - Chino · Bristol-Myers Squibb · NCT06929273A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au
Phase 3 · Inland Psychiatric Medical Group. · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT07424404A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Phase 3 · Inland Psychiatric Medical Group. · Bristol-Myers Squibb · NCT07288567A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Sympt
Phase 4 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT07105111Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
Phase 2 · Inland Psychiatric Medical Group - Chino · Rapport Therapeutics Inc. · NCT07046494Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Phase 3 · Clinical Research Site · Axsome Therapeutics, Inc. · NCT07484217ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Phase 2 · Site 7153 · Alto Neuroscience · NCT07553637Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associate
Phase 3 · Local Institution - 1-141NO1DG · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT05980949A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Dise
Phase 3 · Inland Psychiatric Medical Group. · Bristol-Myers Squibb · NCT06947941A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur
Phase 3 · Inland Psychiatric Medical Group. · Bristol-Myers Squibb · NCT07140913Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
Phase 2 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT07365462NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Phase 3 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT07114874Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W
Phase 2 · Inland Psychiatric Medical Group. · Celgene · NCT06808984A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Ep
Phase 3 · Inland Pyschiatric Medical Group - Chino /ID# 278667 · AbbVie · NCT04777357A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Phase 2 · Inland Psychiatric Medical Group, Inc. - Chino · Tonix Pharmaceuticals, Inc. · NCT07621237A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Phase 3 · Inland Psychiatric Medical Group (IPMG)-Chino · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT06585787Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Phase N/A · Local Institution - 0039 · Bristol-Myers Squibb · NCT07379827NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants W
Phase 3 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT06963021A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With
Phase 2 · Seaport Investigator Site · Seaport Therapeutics · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Phase 2 · Inland Psychiatric Medical Group · ACADIA Pharmaceuticals Inc. · NCT07284667
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.